Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells

Molecular Pharmacology

Volumn 62, Issue 4, 2002, Pages 911-920

  Eisen, Susanne F ^a   Brown, H Alex ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; DRUG METABOLITE; ESTROGEN RECEPTOR; ISOENZYME; PHOSPHOLIPASE D; RALOXIFENE; RECOMBINANT ENZYME; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CATALYSIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INSECT CELL; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; CATALYSIS; ENZYME ACTIVATION; EPITHELIAL CELLS; ESTROGEN ANTAGONISTS; HUMANS; PHOSPHOLIPASE D; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0036783739     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.4.911     Document Type: Article

References (40)

1. Anderson E, Vinson GP, Puddefoot JR, Raven PW, and Gilmore OJA (1986) Steroid sequestration and tightly bound estrogen-protein complexes in human breast tumors and a breast cancer cell line. J Steroid Biochem 24:489-495.
2. Balboa MA, Firestein BL, Godson C, Bell KS, and Insel PA (1994) Protein kinase C alpha mediates phospholipase D activation by nucleotides and phorbol ester in Madin-Darby canine kidney cells. Stimulation of phospholipase D is independent of activation of polyphosphoinositide-specific phospholipase C and phospholipase A2. J Biol Chem 269:10511-10516.
3. Bignon E, Pons M, Dore JC, Gilbert J, Ojasoo T, Miquel JF, Raynaud JP, and De Paulet AC (1991) Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem Pharmacol 42:1373-1383.
4. Brown HA, Gutowski S, Kahn RA, and Sternweis PC (1995) Partial purification and characterization of Arf-sensitive phospholipase D from porcine brain. J Biol Chem 270:14935-14943.
5. Brown HA, Gutowski S, Moomaw CR, Slaughter C, and Sternweis PC (1993) ADP-Ribosylation factor, a small GTP-dependent regulatory protein, stimulates phospholipase D activity. Cell 75:1137-1144.
6. Brown HA and Sternweis PC (1995) Stimulation of phospholipase D by ADP-ribosylation factor. Methods Enzymol 257:313-324.
7. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
8. Chouvet C and Saez S (1984) High affinity cytosol binding sites(s) for antiestrogens in two human breast cancer cell lines and in biopsy specimens devoid of estrogen receptors. J Steroid Biochem 21:755-761.
9. Cohen JS and Brown HA (2001) Phospholipases stimulate secretion in RBL mast cells. Biochemistry 40:6589-6597.
10. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnson NH, Morrow M, et al. (1999) The effect of raloxifane on risk of breast cancer in postmenopausal women; results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 281:2189-2197.
11. Daniel P, Gaskell SJ, Bishop H, Campbell C, and Nicholson I (1981) Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur J Cancer Clin Oncol 17:1183-1189.
12. Exton JH (1999) Regulation of phospholipase D. Biochim Biophys Acta 1439:121-133.
13. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, and Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (Wash DC) 294:1942-1945.
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov M, Atkins J, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388.
15. Fiucci G, Czarny M, Lavie Y, Zhao D, Berse B, Blusztajn JK, and Liscovitch M (2000) Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells. Int J Cancer 85:882-888.
16. Frohman MA and Morris AJ (1999) Phospholipase D structure and regulation. Chem Phys Lipids 98:127-140.
17. Hart MJ, Eva A, Evans T, Aaronson SA, and Cerione RA (1991) Catalysis of guanine nucleotide exchange on the Cdc42Hs protein by the dbl oncogene product. Nature (Lond) 354:311-314.
18. Jordan VC and Koerner S (1975) Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. J Endocrinol 64:193-194.
19. Kiss Z (1994) Tamoxifen stimulates phospholipase D activity by an estrogen receptor-independent mechanism. FEBS Lett 355:173-177.
20. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, and Clarke R (1994) The effect of tamoxifen on the multidrug resistant phenotype in human breast cancer cells: isobologram, drug accumulation and gp-170 binding studies. Cancer Res 54:441-447.
21. Lin R, Bagrodia S, Cerione R, and Manor D (1997) A novel Cdc42Hs mutant induces cellular transformation. Curr Biol 7:794-797.
22. 2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res 50:2753-2758.
23. Min DS, Kwon TK, Park WS, Chang JS, Park SK, Ahn BH, Ryoo ZY, Lee YH, Lee YS, Rhie DJ, et al. (2001) Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts. Carcinogenesis 22:1641-1647.
24. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, and Han JS (2000) Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161:207-214.
25. O'Brian CA, Liskamp RM, Solomon DH, and Weinstein IB (1986) Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 76:1243-1246.
26. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang C, Ballas LM, Hamilton PT, McDonnell DP, et al. (1999) Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β. Proc Natl Acad Sci USA 96:3999-4004.
27. Park SK, Min DS, and Exton JH (1998) Definition of the protein kinase C interaction site of phospholipase D. Biochem Biophys Res Commun 244:364-367.
28. Plowman PN (1993) Tamoxifen as adjuvant therapy in breast cancer. Current status. Drugs 46:819-833.
29. Randazzo PA, Weiss O, and Kahn RA (1992) Preparation of recombinant ADP-ribosylation factor. Methods Enzymol 219:362-369.
30. Singer WD, Brown HA, Bokoch GM, and Sternweis PC (1995) Resolved phospholipase D activity is modulated by cytosolic factors other than Arf. J Biol Chem 270:14944-14950.
31. Singer WD, Brown HA, and Sternweis PC (1997) Regulation of eukaryotic phosphatidylinositol-specific phospholipase C and phospholipase D. Annu Rev Biochem 66:475-509.
32. Skidmore J, Walpole AL and Woodburn J (1972) Effect of some triphenylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 52;289-298.
33. Sung TC, Zhang Y, Morris AJ, and Frohman MA (1999) Structural analysis of human phospholipase D1. J Biol Chem 274:3659-3666.
34. Uchida N, Okamura S, and Kuwano H (1999) Phospholipase D activity in human gastric carcinoma. Anticancer Res 19:671-675.
35. Walker SJ and Brown HA (2002) Specificity of Rho insert-mediated activation of phospholipase D1. J Biol Chem 277:26260-26207.
36. Walker SJ, Wu WJ, Cerione RA, and Brown HA (2000) Activation of phospholipase D1 by cdc42 requires the rho insert region. J Biol Chem 275:15665-15668.
37. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, and Rodenhuis S (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437-442.
38. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, and Mellors A (1995) Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1:1223-1232.
39. Yoshida M, Okamura S, Kodaki T, Mori M, and Yamashita S (1998) Enhanced levels of oleate-dependent and Arf-dependent phospholipase D isoforms in experimental colon cancer. Oncol Res 10:399-406.
40. Zhao Y, Ehara H, Akao Y, Shamoto M, Nakagawa Y, Banno Y, Deguchi T, Ohishi N, Yagi K, and Nozawa Y (2000) Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun 278:140-143.